MedPath

TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation

Not Applicable
Recruiting
Conditions
Tree Nut Allergy
Food Allergy
Registration Number
NCT05521711
Lead Sponsor
Hamilton Health Sciences Corporation
Brief Summary

Tree nut immunotherapy Route Assessment and DEvelopment (TRADE) is a randomized controlled trial that evaluates the efficacy and safety of sublingual immunotherapy and lower, more tolerable, doses of oral immunotherapy than currently in use.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Allergic to tree nut with baseline threshold of 444 mg protein or less and provides consent, and where applicable, assent.
Exclusion Criteria
  1. History of anaphylaxis to tree nut severe enough to cause shock, syncope, or intubation
  2. Eosinophilic or other inflammatory gastrointestinal disease within the past 2 years
  3. Severe (GINA severity class 5) or uncontrolled asthma including exacerbation within past 6 months
  4. Use of biologics, other food immunotherapy or experimental treatment in past 6 months.
  5. Ongoing other allergic diseases severe enough to preclude discontinuing antihistamines for 7 days prior to assessment visits
  6. Pregnancy or significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease; allergy to the oat-based placebo) which would put the participant at excessive risk for food allergic reactions as judged by local investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Eliciting dose thresholds to food challenge1 year
Secondary Outcome Measures
NameTimeMethod
Quality of life1 Year

Food allergy quality of life questionnaire

Trial Locations

Locations (1)

McMaster University Medical Centre

🇨🇦

Hamilton, Ontario, Canada

McMaster University Medical Centre
🇨🇦Hamilton, Ontario, Canada
Heather Le
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.